European Commission Opens 2026 Joint Scientific Consultation Submission Window

European Commission Opens 2026 Third Submission Window for JSCs

The European Commission has announced the opening of the third 2026 submission window for Joint Scientific Consultations (JSCs), a critical step for health technology developers under the new EU HTA Regulation. This provides an opportunity for early alignment with EU HTA bodies. The window, which opened January 7 and closes February 4, 2026, gives pharmaceutical and medtech developers a narrow but high-value chance to shape clinical evidence generation before registrational protocols are locked — directly affecting how their products will be assessed for reimbursement across 27 Member States.

Key Takeaways

• The European Commission opened the third 2026 JSC submission window on January 7, with a hard deadline of February 4, 2026. All requests must be filed via the HTA IT Platform.
• JSCs provide health technology developers with scientific advice on clinical evidence needs for subsequent Joint Clinical Assessments under the EU HTA Regulation, which entered into application in January 2025.
• Four 2026 windows are confirmed: January 7–February 4, April 1–29, June 3–July 1, and September 23–October 21. Briefing document slots extend into June 2026.
• Early registration on the HTA IT Platform is essential — access approval can take several days, and consultation slots within each window are finite.
• No fee applies for JSC submissions. Developers may request parallel consultation with EMA scientific advice to synchronize regulatory and HTA expectations in a single coordinated engagement.

What Is the EU HTA Regulation and Why Do JSCs Matter?

The EU HTA Regulation entered into application in January 2025, establishing a harmonized framework for the clinical assessment of health technologies across all Member States. At its core are Joint Clinical Assessments — single EU-level evaluations that replace the patchwork of national HTA processes for certain medicinal products and medical devices. For companies accustomed to navigating 27 separate reimbursement dossiers, the shift is structural, not incremental.

Joint Scientific Consultations sit upstream of that system. They allow developers to engage EU HTA bodies during clinical development planning — before pivotal trial protocols are finalized — and receive structured feedback on study design, comparator selection, endpoint relevance, and the PICO framework that will govern subsequent JCA submissions. The advice is non-binding, but ignoring it carries real risk: a registrational program that fails to generate evidence aligned with HTA expectations faces delayed or restricted reimbursement across the bloc.

The European Commission manages the submission calendar, while the HTA Coordination Group and its substructures deliver the scientific advice. The process is open to both medicinal products and medical devices, reflecting the regulation's broad scope. For developers in the transition period between national HTA processes and the centralized JCA system, JSCs are the primary mechanism to de-risk evidence generation before committing hundreds of millions to registrational programs.

What Are the 2026 JSC Submission Windows and Deadlines?

The European Commission has confirmed four submission windows for JSCs in 2026. The third window, now open, runs from January 7 to February 4, 2026. The full calendar:

• Window 3: January 7 – February 4, 2026
• Window 4: April 1 – April 29, 2026
• Window 5: June 3 – July 1, 2026
• Window 6: September 23 – October 21, 2026

All requests must be submitted via the HTA IT Platform. The Commission has explicitly flagged that platform access approval may take several days, making early registration a practical necessity rather than a suggestion. Briefing document deadlines extend into mid-2026, with slots available for documents due by April 7, May 4, and June 8, 2026 — meaning developers who file in the current window can secure scientific advice aligned with late-stage development timelines.

A notable feature: developers can request parallel JSC and EMA scientific advice. This mechanism is designed to reduce duplicative regulatory interactions and synchronize clinical development expectations across the evidence generation and market authorization tracks. For global development programs, the parallel pathway compresses what would otherwise be sequential feedback loops into a single coordinated engagement.

How Should BD Teams and Investors Evaluate JSC Timing?

Each JSC window functions as a development catalyst with direct implications for pipeline valuation and competitive positioning. Companies that secure JSC slots gain structured feedback from EU HTA bodies on whether their planned clinical programs will generate evidence sufficient for JCA — effectively a dry run for the assessment that will determine reimbursement negotiations across 27 Member States.

For business development teams, the JSC calendar creates actionable timing signals. A company filing a JSC request in the current window is signaling that a JCA-subject product is advancing through mid-to-late-stage development. Investors tracking these filings — or the absence of filings for expected candidates — can infer development confidence and timeline readiness before public clinical trial updates.

The strategic calculus compounds when considering the parallel EMA-JSC pathway. Developers who synchronize scientific advice with both EMA and HTA bodies reduce the risk of regulatory-authorization-HTA misalignment, a scenario that has historically delayed market access in Europe by 12 to 18 months post-approval. Companies that proactively use JSCs position themselves to compress that gap, which directly affects peak sales assumptions and time-to-revenue models in BD valuations.

The lack of a submission fee lowers the cost of engagement, but the real constraint is capacity. Each window offers a finite number of consultation slots. Developers with products approaching pivotal trial initiation in 2026 or early 2027 should treat the February 4 deadline — and the subsequent April and June windows — as hard planning milestones, not soft targets.

What Is the Difference Between JSC and JCA?

Joint Scientific Consultations enable health technology developers to obtain scientific consultation during the planning of clinical studies and clinical investigations on the information and evidence needs for a subsequent Joint Clinical Assessment. JSCs are advisory and occur before or during clinical development — they are not assessments themselves.

Joint Clinical Assessments are the formal EU-level clinical evaluations conducted after a product receives marketing authorization. JCAs form the clinical basis for national HTA and reimbursement decisions across Member States. JSCs prepare developers for JCAs; they do not replace them. Think of JSCs as the planning consultation and JCAs as the final exam.

For official guidance on the distinction and the JSC submission process, the European Commission's Joint Scientific Consultations page provides detailed procedural documentation, and the EMA's scientific advice overview covers the parallel consultation pathway.

What Is the Joint Scientific Consultation Process?

JSC offers recommendations to health technology developers on their development plans for a medicinal product or medical device, ensuring that evidence meets requirements for a subsequent JCA. This guidance can streamline preparation for JCA and enhance the quality of clinical studies. The process is coordinated by the HTA Coordination Group, with advice delivered by EU HTA bodies drawn from Member State agencies.

Developers submit requests through the HTA IT Platform during designated windows. The submission includes a briefing document outlining the product, its development stage, and specific questions for HTA bodies. Scientific feedback is then provided on the proposed clinical evidence generation plans, covering methodological choices, endpoint selection, and data presentation expectations that will matter at JCA.

Frequently Asked Questions

Related coverage

• ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address
• Bio/Pharma Outlook 2026: Regulatory Updates and Implications
• Rethinking QA/QC at The Future of Bio/Pharmaceutical Analysis 2026